Hebei Lansheng Biotech Co., Ltd.
Beijing Multigrass Formulation Co., Ltd.

After three lost glyphosate-cancer trials, Bayer investors fear litigation ‘avalanche’ will further harm company’s reputationqrcode

Apr. 16, 2020

Favorites Print
Forward
Apr. 16, 2020
By Tim Loh and Eyk Henning

Two influential shareholder advisory groups are split on whether investors should support Bayer AG’s management at its upcoming annual meeting, a year after a damaging no-confidence vote.

Glass Lewis & Co. still sees risks brought about by Bayer’s takeover of agriculture giant Monsanto, advising shareholders to abstain rather than vote to endorse Chief Executive Officer Werner Baumann’s actions in 2019. While Institutional Shareholder Services Inc. recommended backing Baumann and his team, it expressed concern that litigation related to the Roundup weedkiller could further hurt the company’s value and reputation.

Concerns linger over Baumann’s strategic choices after he helped orchestrate the $63 billion deal that brought Bayer an avalanche of U.S. lawsuits from people claiming Roundup causes cancer. Three lost trials and at least 48,000 more suits have spurred investor flight, wiping tens of billions of dollars off Bayer’s valuation.

Bayer acknowledged in February that the losses from Roundup could force it to sell assets, issue new equity or borrow money at unfavorable terms. Bayer insists the herbicide is safe and has appealed the losing verdicts.

Source: Bloomberg

Picture 0/1200

More from AgroNews

Magazine

Annual Review 2020 2020 India Pesticide Suppliers Guide
2020 Market Insight Chinese issue of 2020 Market Insight
2020 CRO & CRAO Manual Chinese issue of 2020 Biologicals Special
I wanna post a press Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

Picture 0/1200

Subscribe to daily email alerts of AgroNews.